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INTRODUCTION
Breast cancer research has been revolutionised 
over the past decade by the advent of gene expression 
profiling, which at the molecular level, has subdivided 
breast cancers into five ‘intrinsic subtypes’ (Luminal A 
and Luminal B, basal-like, HER2 -enriched and a normal 
breast-like group) [1, 2].  Although molecular profiling 
of breast tumours has provided valuable insights into the 
biological behaviour of different subtypes of breast cancer, 
in the clinical/pathology setting classification of breast 
cancer is routinely based on IHC staining for ERα, PR and 
HER2.  Triple negative breast cancers (TNBCs), which 
account for approximately 15% of all breast cancers, are 
characterised by a  lack of ERα, PR expression and HER2 
overexpression, and although the majority of TNBCs share 
similar gene expression profiles with Basal-Like Breast 
Cancers (BLBCs), there is not complete overlap between 
the two groups [3].  The TNBC subtype is associated with 
high mortality rates due to both the aggressive nature 
of the disease and limited treatment options available. 
Lacking ERα expression and HER2 receptor amplification/
overexpression, TNBC patients do not benefit from either 
hormonal or HER2-targeting therapies, and as a result, the 
risk of relapse is 30–40%, compared to less than 25% in 
ERα positive patients treated with endocrine therapies [4]. 
Since there are no targeted treatments available for TNBC, 
these patients are entirely reliant on chemotherapy and the 
current standard of care is to treat with a combination of 
DNA damaging agents, most notably the FEC regimen [5]. 
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ABSTRACT
Triple Negative Breast Cancer (TNBC) is defined by the lack of ERα, PR expression 
and HER2 overexpression and is the breast cancer subtype with the poorest clinical 
outcomes.  Our aim was to identify genes driving TNBC proliferation and/or survival 
which could represent novel therapeutic targets. 
We performed microarray profiling of primary TNBCs and generated differential 
genelists based on clinical outcomes following the chemotherapy regimen FEC 
(5-Fluorouracil/Epirubicin/Cyclophosphamide -‘good’ outcome no relapse > 3 years;  
‘poor’ outcome relapse < 3 years). Elevated expression of thromboxane A2 receptor 
(TBXA2R) was observed in ‘good’ outcome TNBCs. TBXA2R expression was higher 
specifically in TNBC cell lines and TBXA2R knockdowns consistently showed dramatic 
cell killing in TNBC cells. TBXA2R mRNA and promoter activities were up-regulated 
following BRCA1 knockdown, with c-Myc being required for BRCA1-mediated 
transcriptional repression. 
We demonstrated that TBXA2R enhanced TNBC cell migration, invasion and 
activated Rho signalling, phenotypes which could be reversed using Rho-associated 
Kinase (ROCK) inhibitors. TBXA2R also protected TNBC cells from DNA damage by 
negatively regulating reactive oxygen species levels.  In summary, TBXA2R is a novel 
breast cancer-associated gene required for the survival and migratory behaviour of 
a subset of TNBCs and could provide opportunities to develop novel, more effective 
treatments.
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Whilst some TNBC patients relapse rapidly 
following primary chemotherapy, many patients achieve a 
complete pathologic response (pCR) and have a favourable 
prognosis [6–8].  However, patients with residual disease 
have a short overall survival and very poor outcomes, 
with one study reporting a median survival of only 6 
months following manifestation of distant metastasis [9]. 
A further obstacle to treatment of TNBCs is the highly 
heterogeneous nature of this disease. Numerous attempts 
have recently been made to sub-classify TNBC in order 
to identify novel (i) prognostic markers, (ii) predictive 
markers of chemotherapy responses and (iii) potential 
therapeutic targets [10, 11] and as many as 10 different 
subtypes of TNBC have now been described.  This 
highlights the importance of identifying novel therapeutic 
targets for TNBC patients and a number of avenues of 
research are currently being explored such as PIK3/AKT 
and mTOR inhibitors, alongside biomarkers to stratify 
which subpopulations of TNBCs are most likely to 
respond to them [12, 13].
The thromboxane A2 receptor (TBXA2R) is a 
seven-transmembrane domain-spanning G-protein coupled 
receptor (GPCR) predominantly expressed in platelets 
and involved in platelet activation and aggregation, but 
can activate a multitude of signalling cascades and thus 
regulate a diverse range of cellular processes such as 
vasoconstriction of smooth muscle cells, inflammatory 
responses, cell adhesion and motility, proliferation and 
cell survival [14].  The oncogenic role of TBXA2R in 
lung cancer has been particularly well studied in which 
it enhances cell proliferation, migration and invasion, and 
thromboxane A2 synthase (TBXAS) inhibits apoptosis via 
negative regulation of reactive oxygen species (ROS) [15–
18].  High expression levels of TBXA2R have also been 
observed in bladder cancer and prostate cancer cell line 
models leading to increased migratory capacity [19–21]. 
Thromboxane production has been shown to be increased 
in human mammary carcinomas in comparison to matched 
normal breast tissue, and correlated with increased tumour 
size and metastatic potential as well as absence of ERα/
PR [22].  Additionally, analysis of TBXA2R mRNA 
levels in 120 human breast tumours and 32 non-cancerous 
mammary tissues showed higher levels of TBXA2R 
transcript were significantly associated with higher grade 
tumours and shorter disease free survival [23].  Despite 
the indications that thromboxane signalling is associated 
with poor prognosis in breast cancer, few studies have 
investigated the functional role of this pathway in breast 
cancer. 
This current study shows that TBXA2R is highly 
expressed specifically in TNBC cell line models and 
loss of expression causes a dramatic decrease in not only 
cell viability and proliferation but also cell migration 
and invasion.  We have also shown for the first time 
that TBXA2R is transcriptionally repressed by BRCA1 
(a tumour suppressor often mutated or down-regulated 
in TNBC), providing a potential mechanism by which 
TBXA2R is up-regulated in TNBC/BLBCs. We have 
shown that TBXA2R may promote oncogenesis via the 
Rho/ROCK pathway and evidence is presented for ROCK 
inhibition as a potential treatment option for TBXA2R 
over-expressing TNBCs. Finally, TBXA2R is indicated 
as a negative regulator of ROS and a potential predictive 
marker of chemotherapy response in TNBC. 
RESULTS
TBXA2R expression is important for TNBC cell 
viability
An siRNA library screening approach was employed 
to measure effects on cell viability in TNBC cell lines 
following siRNA knockdown (using 3 independent 
siRNA sequences) of a number of genes differentially 
expressed in ‘good’ versus ‘poor’ outcome TNBC profiles 
(Supplementary Figure S1).  Substantial reductions in 
cell viability as measured by MTT assay were observed 
following siRNA knockdown of multiple genes (relative 
to scrambled siRNA control) with pronounced viability 
effects observed with TBXA2R depletion in all 4 TNBC 
lines (MDA-MB-231, Hs578T, MDA-MB-468 and 
SUM-PT-149; Figure 1A).  Triplicate knockdowns with 
two additional independent siRNAs, followed by crystal 
violet staining (to quantify cell density) again showed 
that depletion of TBXA2R reduced the viability of TNBC 
cell lines (Figure 1B).  Conversely, minimal effects on 
cell proliferation were observed following reduction of 
TBXA2R in the non-tumorigenic basal breast line hTERT-
HME-1 by both MTT assay (Figure 1C) and crystal violet 
staining (Figure 1D). TBXA2R mRNA expression was 
then measured in a panel of breast cell lines by quantitative 
real time PCR (qPCR), showing that TBXA2R expression 
is specifically elevated in TNBC cell lines relative to non-
tumorigenic breast, HER2-overexpressing or luminal 
breast cancer lines (Figure 1E).  
TBXA2R is transcriptionally repressed by 
BRCA1
To identify the mechanism of transcriptional 
regulation of TBXA2R in breast cancer cells, a number of 
key transcription factors were depleted by siRNA in T47D 
and MCF7 cell lines and changes in TBXA2R mRNA 
levels were measured by qPCR.  These two breast cancer 
lines were chosen since they are known to express wild-
type BRCA1 and luminal differentiation markers (some of 
which we targeted here). Figure 2A shows a statistically 
significant increase in TBXA2R gene expression 
following siRNA knockdown of BRCA1 in T47D 
cells and GATA3 in MCF7 cells.  This is an interesting 
observation since our group have previously shown that 
BRCA1 and GATA3 interact to co-repress another basally-
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restricted oncogene, FOXC1 [24].  Efficiencies of siRNA 
knockdowns were comparable in both cell lines (shown 
immediately underneath).  Luciferase reporter assays 
were carried out in T47D cells following transfection 
of a proximal region of the TBXA2R promoter (600 bp 
upstream of the transcriptional start site, TSS).  Following 
depletion of BRCA1, luciferase activity was significantly 
increased indicative of enhanced TBXA2R promoter 
activity (Figure 2B) in agreement with TBXA2R gene 
expression (Figure 2A and 2B).  However, in contrast 
to increased TBXA2R mRNA following reduction 
of GATA3, TBXA2R promoter activity was reduced 
suggesting that GATA3 is not acting as a co-repressor 
with BRCA1 within this proximal promoter region with 
western blot analysis confirming knockdown of both 
BRCA1 and GATA3 at the protein level (Figure 2B). To 
define the mechanism of BRCA1-mediated repression 
of TBXA2R, we used exonuclease mapping to generate 
sequentially shorter TBXA2R promoter luciferase reporter 
constructs to assess transcriptional activity following 
transfection of BRCA1 siRNA.  Figure 2C shows BRCA1 
regulation is lost between –323 and –186 bp relative to 
the Transcriptional Start Site (TSS) of TBXA2R.  As 
BRCA1 cannot bind DNA in a sequence specific manner, 
we used TF Search and Alibaba online resources to 
predict potential transcriptional regulators. These showed 
Figure 1:  TBXA2R is a basal-specific marker and promotes survival of TNBC cells.  (A) Cell viability (as measured 
by MTT assay) following transfection of 3 independent TBXA2R siRNAs relative to scrambled siRNA control in the TNBC cell lines 
Hs578T, MDA-MB-231, MDA-MB-468 and SUM-PT-149 with FOXC1 siRNA was used as a positive transfection control.  (B) Graphs 
showing absorbance values for crystal violet staining 72 hr post-transfection with scrambled siRNA control, TBXA2R siRNA#1 and #2 in 
Hs578T, MDA-MB-231 and SUM-PT-159 cells (representative clonogenic images underneath each graph). (C) Cell viability (as measured 
by MTT assay) following the same TBXA2R siRNA knockdowns as in (A) in the non-tumourigenic hTERT-HME1 cell line with (D) the 
corresponding TBXA2R knockdowns and crystal violet absorption as outlined in (B). Absorbance values following reabsorption of crystal 
violet represent results from 3 biological replicates. Data was analysed by one-way ANOVA with Dunnett’s post-hoc test where *P < 0.05, 
**P < 0.01, ***P < 0.001 and ns = not significant. (E) qPCR analysis of TBXA2R mRNA levels in a panel of breast cancer and normal 
breast cell lines, normalised to β-tubulin mRNA levels.
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potential binding sites for a number of known BRCA1-
interactors including SP-1, AP2, GATA family and c-Myc 
(Figure 2C).  ENCODE analyses demonstrated ChIP-seq 
experiments which showed potential overlapping binding 
regions for BRCA1 and c-Myc on the TBXA2R promoter 
in HeLa cells (Figure 2D).  
c-Myc and BRCA1 act as co-repressors of 
TBXA2R transcription
C-Myc has been well documented as a BRCA1 
interacting protein and an important protein for the 
ability of BRCA1 to transcriptionally repress basal-
like genes such as psoriasin and p-cadherin [25, 26]. 
Physical interaction between BRCA1 and c-Myc has also 
been shown specifically in T47D cells [26], therefore, 
we hypothesised this may be a likely mechanism 
through which TBXA2R is repressed.  In agreement 
with this, Figure 3A shows TBXA2R promoter activity 
was increased at –585 bp and –323 bp following 
transfection of c-Myc siRNA and regulation is lost at 
–186 bp upstream of the TSS.  This followed the same 
trend as BRCA1 knockdown (although c-Myc siRNA 
did not reach statistical significance).  Figure 3B shows 
increased TBXA2R mRNA in T47D cells following 
depletion of c-Myc.  BRCA1 and c-Myc binding to 
the TBXA2R promoter was confirmed by chromatin 
immunoprecipitation (ChIP) assay.  Figure 3C and 3D 
show enrichment on the –324/–177 bp region (as analysed 
by qPCR) of the TBXA2R promoter (relative to a negative 
upstream region) following immunoprecipitation of 
chromatin using both BRCA1 and c-Myc antibodies 
respectively, demonstrating that both these proteins are 
bound to this region of the promoter.  Indeed, qPCR of 
Figure 2:  TBXA2R is negatively regulated by BRCA1. (A) qPCR analysis of TBXA2R mRNA levels normalised to β-tubulin 
mRNA in T47D and MCF7 cell lines following siRNA knockdown of p53, p63, ΔNp63, JAG1, ERα, GATA3 and BRCA1. Knockdown 
efficiencies are also shown for each gene immediately underneath.  (B) Luciferase reporter gene assay of TBXA2R promoter region 
(–600 bp upstream of the Transcriptional Start Site, TSS) relative to pGL3 empty vector, following siRNA knockdown of BRCA1 and 
GATA3 in T47D cells.  Matched qPCR shows TBXA2R mRNA levels 72 hr post-transfection of BRCA1 and GATA3 siRNA, and western 
blot analysis confirmed depletion of BRCA1 and GATA3 protein levels. (C) Luciferase reporter assay of T47D cells transfected with 
sequentially shorter TBXA2R promoter constructs following BRCA1 depletion, and underneath shows potential transcription factor 
binding sites within this region as predicted by the Alibaba online resource.  Data represents 3 independent replicates analysed by one-
way ANOVA with Dunnett’s (A) or Bonferroni’s (B,  C) post-hoc tests; *P < 0.05, **P < 0.01, ***P < 0.001 and ns = not significant. (D) 
ENCODE analysis of BRCA1 and c-Myc binding on TBXA2R promoter region of interest in HeLa cells. 
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immunoprecipitated DNA showed that following c-Myc 
depletion BRCA1 could not be localised to the TBXA2R 
promoter region, indicating that c-Myc is required for 
BRCA1 recruitment (Figure 3E).    
TBXA2R signals through the Rho/ROCK 
pathway in TNBC cells
The molecular mechanisms by which TBXA2R 
maintains cell viability in TNBC are currently undefined. 
Previous studies have shown TBXA2R can regulate 
a number of pathways involved in oncogenesis, most 
notably through the MAPK/ERK, AKT and Rho 
pathways [14, 15, 21, 27].  Western blot analysis shows 
minimal variation in levels of phosphorylated ERK1/2 in 
MDA-MB-231 (Figure 4A) or levels of phosphorylated 
AKT(Ser473) in SUM-PT-159 cells (Figure 4B) 
following independent TBXA2R siRNA knockdowns. 
Depletion of TBXA2R leads to significantly reduced 
levels of phosphorylated myosin light chain 2 (pMLC2) 
in both MDA-MB-231 cells and SUM-PT-159 cells 
(Figure 4C). MLC2 is known to be phosphorylated (and 
Figure 3:  BRCA1 is recruited to the TBXA2R promoter by c-Myc.  (A) Luciferase reporter assays of TBXA2R promoter 
constructs (–585, –323 and –186 bp upstream of the TSS) 72 hr post-transfection with BRCA1 and c-Myc siRNA.  Data normalised to 
pGL3 Basic and scrambled siRNA control (n = 3). (B) qPCR analysis of TBXA2R mRNA levels following siRNA knockdown of c-Myc 
(with mRNA values normalised to β-tubulin mRNA). (C) ChIP assay in T47D cells showing fold enrichment of BRCA1 and (D) c-Myc 
binding to the TBXA2R promoter relative to a negative upstream region as analysed by qPCR. Data was analysed by unpaired one-tailed 
t-test (n = 3); *P < 0.05, ***P < 0.001. (E) ChIP assay showing differential recruitment of BRCA1 to the TBXA2R promoter following 
siRNA depletion of c-Myc. ChIP data was normalised to chromatin input. Data was analysed by one-way ANOVA and Bonferroni’s post-
hoc test; *P < 0.05 and ns = not significant; n = 4 replicates over two independent experiments.
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activated) downstream of Rho/ROCK and has been used 
as a reliable surrogate marker of Rho pathway activation. 
To confirm the involvement of the Rho pathway, direct 
Rho activation assays were carried out in which a GST-
Rhotekin binding domain fusion protein was used to 
specifically immunoprecipitate the active GTP-bound 
form of Rho.  Levels of active Rho A and C isoforms 
analysed by western blot show decreased levels of both 
active RhoA and C following TBXA2R knockdown 
(Figure 4D).  However, only reductions in levels of RhoC 
were statistically significant.  To show which members of 
the Rho pathway effect cell viability (in a manner similar 
to TBXA2R) individual members of the Rho pathway 
were knocked down by siRNA and cell viabilities were 
analysed by crystal violet staining.  Specifically, RhoA 
and ROCK2 knockdowns both significantly decreased 
cell viability in MDA-MB-231 cells (Figure 4E) but 
showed minimal effects on ‘normal’ hTERT-HME-1 cell 
viability (Figure 4F), recapitulating the previously shown 
TBXA2R siRNA effects. 
Figure 4:  ROCK/Rho pathway is activated by TBXA2R. (A) Western blot analysis of total and phosphorylated ERK1/2 in MDA-
MB-231 and (B) total and phosphorylated AKT (Ser 473) levels in SUM-PT-149 cells 72 hr post-transfection of 2 independent TBXA2R 
siRNAs. Densitometry values were normalised firstly for total ERK to β-tubulin and then phosphorylated values were normalised against 
total ERK/β-tubulin. (C) Western blot analysis of total and phosphorylated MLC2 (Ser 19) levels in SUM-PT-159 and MDA-MB-231 cells 
72 hr post-transfection with 2 independent TBXA2R siRNAs with accompanying graphs showing densitometry values for phospho-MLC2 
(Ser 19) relative to total MLC2 levels in SUM-PT-159 cells. (D) Western blot analysis of GTP-RhoA and GTP-RhoC levels were performed 
in the same two TNBC cell lines 72 hr post-transfection with 2 independent TBXA2R siRNAs, with accompanying graphs showing 
densitometry values for active Rho relative to total Rho levels.  GAPDH was used as a loading control in (A–D) and blots were quantified 
by densitometry of 3 independent replicates. (E) Graphs showing absorbance values (n = 3) for crystal violet staining of MDA-MB-231 
and (F) hTERT HME-1 cells 72 hr post-transfection with RhoA, RhoC, ROCK1 and ROCK2 siRNAs with representative images of plates 
underneath each graph. Data was analysed by one-way ANOVA with Dunnett’s post-hoc test (A, B, D) or unpaired two-tailed t-test (C, E, 
F) ; **P < 0.01.
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To unambiguously confirm that the phenotypic 
effects that we have observed where wholly due to 
TBXA2R and not to non-specific targeting via siRNA 
knockdowns, we performed a rescue experiment. Here we 
stably expressed exogenous TBXA2R in a TNBC cell line 
and then knocked down endogenous TBXA2R with an 
siRNA oligonucleotide (designed against the 5′UTR region 
of TBXA2R mRNA in order to target only the endogenous 
mRNA) prior to performing an array of phenotypic 
readouts.  As Supplementary Figure S4 shows, we could 
demonstrate that expression of exogenous TBXA2R back 
into TBXA2R 5′UTR siRNA depleted MDA-MB-231 
cells (exogenous TBXA2R qPCR shown in (a)) totally 
rescued cell viability (b), cell migration (c) (assessed 
by wound closure) and activation of Rho signalling 
(d) (assessed by phospho-MLC2 immunoblotting and 
quantified by densitometry relative to total MLC2, Figure 
4E). These data together categorically demonstrate that the 
TBXA2R signalling pathway is a key driver of multiple 
oncogenic phenotypes in TNBC cells.
ROCK inhibition decreases cell viability, 
migration and invasion in TBXA2R-expressing 
TNBCs
Since the knockdown studies from Figure 4 show 
that ROCK activity may maintain cell viability of TNBCs 
downstream of TBXA2R we wanted to assess the effects 
of ROCK inhibitors. A cell viability graph following 
treatment with ROCK inhibitor Y39983 demonstrated 
a lower IC50 value for MDA-MB-231 TNBC cells 
compared to hTERT-HME-1 (Figure 5A), suggesting 
a potential therapeutic window for ROCK inhibitor 
treatment of TNBCs.  In addition to our observations on 
cell viability, previous studies have also reported TBXA2R 
to augment cell migration and invasion [17, 18].  Wound 
scratch assays demonstrated that TBXA2R depletion 
decreased cell migration (Figure 5B), whilst Matrigel-
coated Boyden chamber assays showed reductions in cell 
invasion in both MDA-MB-231 and SUM-PT-159 cells 
(Figure 5C). 
TBXA2R antagonises endogenous ROS levels in 
TNBC cell lines and is a potential biomarker of 
TNBC clinical outcomes
Since TBXA2R has well documented roles in 
oxidative stress responses we postulated that reducing 
TBXA2R levels may induce apoptosis via generation of 
intracellular oxidative stress via ROS.  The thromboxane 
pathway has previously been shown to regulate levels 
of ROS which are a major endogenous source of DNA 
damage in multiple tissue types [28]. Levels of the 
early DNA damage marker γH2AX were measured by 
immunoblot  in Hs578T and SUM-PT-159 cells which 
showed increased γH2AX in both cell lines (quantified by 
densitometry) following triplicate independent TBXA2R 
siRNA knockdowns (Figure 6A).  The increase in DNA 
damage following TBXA2R knockdown was also 
demonstrated by foci counts following immunofluorescent 
staining for γH2AX and 53BP1 in both Hs578T and SUM-
PT-159 cells (Figure 6B and Supplementary Figure S2). 
We also observed increased levels of ROS following 
TBXA2R siRNA knockdowns in both Hs578T and SUM-
PT-159 cell lines (Figure 6C).  In contrast, over-expression 
of TBXA2R in non-tumorigenic HME-1 cells led to 
decreased intracellular ROS levels and treatment with 
the TBXA2R agonist U46619 reduced ROS levels in a 
dose dependent manner (Figure 6C) suggesting TBXA2R 
levels may be important in promoting cell viability by 
counteracting endogenous ROS generation.  TBXA2R 
clearly has a role in maintaining and driving pathogenic 
features of TNBC cell lines but we were also interested 
in testing its utility as a potential prognostic biomarker 
of clinical outcome, or as a predictive biomarker of DNA 
damaging chemotherapy responses in TNBC patients. 
Using publically available gene expression data we 
observed that TBXA2R (as predicted given that it is a 
basally restricted marker) represents a poor prognosis 
marker of breast cancer overall using KM plotter 
(Figure 6D, p = 0.038, HR 1.84). We internally validated 
immunohistochemical (IHC) staining for TBXA2R 
and performed IHC on an in-house tissue microarray 
containing 63 TNBC cases (3 tumour cores from each 
case) with 5 year clinical follow-up. Measuring Overall 
Survival as a clinical end-point, we observed a non-
significant trend that increased TBXA2R expression was a 
predictor of good outcome in TNBCs (Figure 6E, p-value 
= 0.118, HR 1.87) but this trend became statistically 
significant only when FEC treated patients (n = 33) were 
included in the comparison (Figure 6F, p-value = 0.0178, 
HR 5.3). Similar results were observed using Relapse Free 
Survival as clinical end-point (Supplementary Figure S3A 
and S3B, respectively).  Together these analyses indicate 
that TBXA2R may possess utility as a predictive marker of 
clinical outcomes in TNBC following FEC chemotherapy.
DISCUSSION
In this study, we have identified TBXA2R as a 
novel survival factor for breast cancer which specifically 
maintains cell viability of TNBC cells.  A substantial 
decrease in cell viability was observed following 
TBXA2R siRNA knockdowns in multiple TNBC cell 
lines, while lesser effects were observed on the growth 
of non-tumorigenic basal breast cell lines. We present 
evidence that (i) TBXA2R is transcriptionally repressed 
by a BRCA1/c-Myc complex, (ii) components of the Rho/
ROCK pathway may be important mediators of TBXA2R 
signalling in TNBCs, (iii) TBXA2R may have roles in 
controlling endogenous ROS levels and DNA damage and 
(iv) whilst this receptor is a biomarker of poor prognosis 
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in breast cancer overall, it may possess potential to serve 
as a predictive marker of good outcomes to DNA damage 
therapies in TNBCs. So whilst TBXA2R may be expressed 
at higher levels in good outcome TNBCs and represent 
a survival factor for this subpopulation of TNBCs, its 
expression may also be a useful marker of which TNBCs 
possess an underlying DNA repair defect.
TBXA2R can activate a diverse range of signalling 
pathways and has been implicated in the pathogenesis 
of many diseases, including cancer.  Consistent with our 
findings that TBXA2R is highly expressed in a number of 
breast tumours, Watkins et al. have shown that TBXA2R 
mRNA is preferentially expressed in breast tumours 
in comparison to normal breast tissue, and a separate 
study showed TBXA2R gene expression was elevated 
in inflammatory breast cancer, however, the functional 
significance of TBXA2R in breast cancer has not been 
explored [23, 29]. 
The TBXA2R promoter has been mapped and Prm1 
is the major promoter for transcriptional regulation of 
the predominant TBXA2Rα isoform [30, 31].  However, 
this is the first report that BRCA1 is a transcriptional 
repressor of TBXA2R.  Our results suggest BRCA1 
and c-Myc act as negative regulators of TBXA2R 
transcription by forming a functional transcriptional 
repressor complex on the TBXA2R promoter.  Previous 
studies have shown the physical interaction of BRCA1 
and c-Myc by both the yeast-2-hybrid method [32] and by 
co-immunoprecipitation in T47D [26], and the BRCA1/c-
Myc complex has been shown to repress transcription 
at the promoters of a number of genes including 
CDC25A and hTERT [32, 33].  It is also interesting that 
BRCA1/c-Myc has been shown to repress transcription 
of p-Cadherin and psoriasin genes, both of which are 
preferentially expressed within the basal phenotype [25, 
26].  Since BRCA1 is commonly inactivated in BLBC 
[34] it is perhaps not surprising that a number of basal 
markers including TBXA2R are negatively regulated by 
BRCA1.  We suggest that the emergence of aggressive 
phenotypes observed following loss of BRCA1 function 
Figure 5:  ROCK inhibitors as a potential therapeutic strategy for TBXA2R-expressing TNBCs.  (A) Dose-response curve 
showing cell viabilities (as analysed by MTT assay) of hTERT-HME1 and MDA-MB-231 cells following 48 hr treatment with a range of 
concentrations of the ROCK inhibitor Y39983. IC50 values for both cell lines are shown.  (B) Micrographs of wound scratch experiments 
at 0 hr and 8 hr in Hs578T cells, 48 hr post-transfection with scrambled siRNA and 2 independent TBXA2R siRNAs. Graph showing 
quantification of wound closure is also shown on right (n = 3), analysed by one way ANOVA with Dunnett’s post-hoc test; **P < 0.01, 
***P < 0.001, ns = not significant. (C) Matrigel-coated Boyden chamber invasion assays in MDA-MB-231 and SUM-PT-159 cells showing 
the percentage of cells invaded relative to the total number of cells, following transfection with scrambled and two independent TBXA2R 
siRNAs. Data represents 3 independent replicates and was analysed by one way ANOVA with Dunnett’s post-hoc test; *P < 0.05.
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Figure 6: TBXA2R knockdown induces markers of DNA damage and ROS in TNBCs with TBXA2R expression 
correlating with TNBC clinical outcomes. (A) Western blot analysis of γH2AX levels in Hs578T and SUM-PT-159 cells 72 hr post-
transfection with 3 independent TBXA2R siRNAs or scrambled siRNA control. β-tubulin was used as a loading control. Graphs on right 
show γH2AX levels from 3 biological replicates quantified by densitometry and analysed by one way ANOVA with Dunnett’s post-hoc 
test; *P < 0.05, **P < 0.01. (B) Merged images of immunofluorescent staining of Hs578T and SUM-PT-159 with γH2AX (red) and 53BP1 
(green) antibodies following transfection of 3 independent TBXA2R siRNAs (60x magnification). Foci were counted in > 100 cells from 
4 different fields and percentage of cells with > 5 foci was calculated. Data is representative of 3 independent experiments analysed by one 
way ANOVA with Dunnett’s post-hoc test; *P < 0.05, **P < 0.01. (C) Flow cytometry analysis of fluorescent DCF formed by oxidation 
of non-fluorescent carboxy-2′7′-dichlorofluorescein (H2DCF) substrate to quantify ROS levels.  ROS assay was carried out 48 hr post-
transfection with 3 independent TBXA2R siRNAs in Hs578T and SUM-PT-159 cells, 1 hr post-treatment with U46619 (100, 200 or 300 
nM) in MDA-MB-468 cells and 48 hr following over-expression of TBXA2R in HME-1 cells. (D) Kaplan-Meier curves from publically 
available metadata (KM Plotter) showing overall survival of unselected (all subtype) breast cancer patients. (E) Kaplan-Meier curves from 
IHC staining of an in-house tissue microarray of TNBC patients (n = 63) showing that increased TBXA2R expression correlates with 
Overall Survival (OS) of TNBCs (p = 0.118, HR 1.87). (F) Kaplan-Meier curves from IHC staining of the same in-house tissue microarray 
of TNBC patients (n = 63) (described in E), showing that increased TBXA2R expression correlates significantly with TNBC patients 
stratified for treatment with DNA damaging (FEC) chemotherapy (p = 0.0174, HR 5.3). 
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in breast cancer cells [35] may be partly due to the de-
repression of TBXA2R.  In contrast to BRCA1, c-Myc is 
often amplified in TNBC/BLBCs and has been particularly 
associated with loss of functional BRCA1 [36], therefore, 
further investigation is required into the effect of c-Myc 
on TBXA2R transcription in the absence of BRCA1. 
However, it has been suggested that BRCA1 may exert 
tumour suppressive effects by repression of c-Myc 
activated genes and while the tricomplex of BRCA1/
Nmi/c-Myc represses hTERT transcription, c-Myc alone 
transcriptionally activates hTERT. Therefore, loss of 
BRCA1 in basal breast cells may alter the transcriptional 
properties of c-Myc [33].  Accordingly, overexpression of 
BRCA1 increases c-Myc binding to promoters of c-Myc/
BRCA1 repressed genes, indicating BRCA1 may stabilise 
c-Myc to these promoters [25, 33].  
Since the major role of TBXA2R involves platelet 
activation, this raises the possibility that direct therapeutic 
targeting of the receptor as an anti-cancer strategy may 
compromise haemostasis and would potentially be a 
contraindication for patients with bleeding disorders. 
TBXA2R activation of Rho signalling coupled to 
TNBC-specific decreases in cell viabilities following 
knockdown of RhoA and ROCK1/2 indicate that ROCK 
inhibition may be a potential therapeutic intervention in 
TBXA2R over-expressing TNBC.  Rho, a small GTPase 
downstream of Gα
12/13
, is one of the major TBXA2R-
coupled G-protein families and activation of TBXA2R 
in platelets stimulates this pathway resulting in platelet 
shape change mediated via the phosphorylation of MLC 
[37].  There are 3 Rho isoforms but little evidence of Rho 
isoform-specific effectors, so the mechanisms by which 
the isoforms exert differential effects are unknown, but 
RhoA and C tend to exhibit oncogenic effects in a number 
of cancers whereas RhoB suppresses tumourigenesis 
[38].  In breast cancer, RhoA and RhoC are both over-
expressed and knockdown of each isoform decreased cell 
proliferation, migration and invasion in TNBC cell line 
MDA-MB-231 [39].  A specific role for RhoC has also 
been demonstrated in a mouse mammary adenocarcinoma 
model in which RhoC depletion abolished occurrence 
of lung metastasis [40].  In the current study, we have 
shown RhoA has more pronounced effects on cell 
viability of TNBC cells (similar to TBXA2R), than RhoC. 
However, TBXA2R knockdown demonstrated a greater 
depletion of active RhoC than RhoA [40, 41].  Together, 
this raises the possibility that activation of both of these 
Rho proteins may be responsible for the increase in cell 
proliferation, migration and invasion of TNBC observed 
with TBXA2R, but further investigation is required to 
determine if TBXA2R mediates these individual effects 
via specific Rho members.  While the Rho/ROCK pathway 
is a well-established mediator of cell migration, reports 
of the effects of the Rho/ROCK pathway on cell survival 
are conflicting, with ROCK mediating both pro- and anti-
apoptotic functions depending on the cellular context.  For 
example, several reports support a pro-apoptotic role for 
ROCK in endothelial cells and erythroblastic TF-1 cells 
[42, 43] and in direct contrast to our findings, Harenburg 
et al. have found that TBXA2R-mediated Rho/ROCK 
activation causes apoptosis of immature thymocytes 
[44]. On the other hand, ROCK inhibition in anaplastic 
thyroid cancer cells and in glioma cells increased caspase-
dependent apoptosis, indicating ROCK can also act as an 
anti-apoptotic protein in certain cells [45, 46].  
In terms of therapeutics, a number of effective small 
molecule ROCK inhibitors have been developed, and 
the ROCK inhibitor, Fasudil, is already in clinical use in 
Japan for the treatment of sub-arachnoid haemorrhage, 
which has established the safety of these compounds 
[47].  Furthermore, previous studies have shown the 
metastasis-promoting ability of the Rho/ROCK pathway 
[21, 48] and demonstrated that ROCK inhibitors can 
impede breast cancer progression in vitro [49].  However, 
ROCK inhibitors have not yet progressed to clinical trials 
as anti-cancer agents in the UK or US.  The discovery 
of TBXA2R as a driver of the oncogenic effects of Rho/
ROCK in TNBCs presents the novel possibility that 
TBXA2R could be used as a biomarker to predict which 
patients may respond to treatment with ROCK inhibitors. 
This is of utmost importance since many clinical trials 
have failed in recent years due to poor patient selection, 
particularly for treatment of poorly defined TNBCs [50, 
51].  Whilst PARP inhibitors have shown clinical utility in 
BRCA1/BRCA2 mutant breast and ovarian cancers, the 
story is much less clear in the majority of TNBCs, where 
surrogate markers of BRCA1 deficiency have not yet been 
identified. Our data indicate that ROCK inhibitor treatment 
may be a potential therapeutic strategy in TBXA2R-
expressing/BRCA1-low TNBC patients for whom no 
targeted therapies are currently available. The fact that 
TBXA2R is elevated in the context of BRCA1 deficiency 
and predicts for favourable responses preferentially to 
FEC treatment would suggest it may possess utility as 
a predictive marker of good outcome following DNA 
damaging therapies in TNBCs. Clearly much more work 
is needed to truly evaluate the utility of both ROCK 




All cell lines were maintained as previously 
described [52] and were stored at 37°C in a humidified 
incubator at an atmosphere of 5% carbon dioxide in air.
RNA extraction, cDNA synthesis and qPCR
Isolation of RNA from cell lines was performed 
using phenol-based RNA STAT-60™ (Amsbio, Abingdon, 
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UK) according to manufacturer’s instructions.  RNA was 
reverse transcribed using the Transcriptor First Strand 
cDNA Synthesis Kit (Roche, Burgess Hill, UK) according 
to manufacturer’s directions.  Quantitative real-time PCR 
(qPCR) was carried out on the LightCycler® 480 (Roche) 
using Light Cycler® 480 SYBR Green I Master kit (Roche) 
following manufacturer’s recommendations.  qPCR primer 
sequences are listed in Supplementary Table S1.
siRNA transfections
siRNA was transfected into cells using either 
Lipofectamine® RNAiMax (Invitrogen, Paisley, UK 
(reverse transfection)) or Oligofectamine™ (Invitrogen 
(forward transfection)) according to manufacturer’s 
protocol.  siRNA sequences are listed in Supplementary 
Table S2.
TBXA2R rescue experiments
TBXA2R was PCR cloned into the BamHI site 
of the retroviral vector pBabePuro. The pBabePuro-
TBXA2R and  pBabePuro EV constructs were transfected 
into Phoenix-Ampho 293T cells and after 48 hours virus 
containing media were collected, filtered and overlaid onto 
MDA-MB-231 cells overnight. Following removal of the 
transduction media cells were placed in selection media 
(1 µg/ml Puromycin) alongside a non-infected, negative 
control plate and cultured for up to 2 weeks. The EV and 
TBXA2R stably expressing mixed cell populations were 
then verified by qPCR for exogenous TBXA2R expression 
using vector-insert qPCR primers (Supplementary 
Table S1) and used for the phenotypic assays shown in 
Supplementary Figure S4.
Cell viability assays
To assess cell viability, cells seeded in 96-well 
plates were incubated until an appropriate time-point at 
which 10 μl MTT ((5 mg/ml) Sigma-Aldrich, Dorset, UK) 
was added per well and incubated at 37°C with 5% CO
2
 
for 2 hr.  After removing media, 100 μl DMSO (Sigma-
Aldrich) was added per well.  Similarly, at defined time-
points cells grown in 6-well plates were washed with PBS 
and incubated with crystal violet at room temperature for 
15 min.  The crystal violet was then rinsed off, left to air dry 
and reabsorbed in 0.1 M sodium citrate.  The absorbance 
values for both MTT and crystal violet were read at a 
wavelength of 570 nm using the Biotrak II Visible plate 
reader (Amersham, GE Healthcare, Buckinghamshire, UK).
Luciferase reporter rssays (including 
exonuclease mapping)
Luciferase constructs were transfected into T47D 
using the GeneJuice transfection reagent (EMD Millipore, 
Darmstadt, Germany) according to manufacturer’s 
recommendations. Constructs used include pGL3 Basic 
empty vector, Renilla expression construct, pGL3 
containing TBXA2R 600 bp promoter construct and pGL3 
vector containing shorter TBXA2R promoter constructs 
generated using the exonuclease mapping ERASE-A-
BASE kit (Promega, Southampton, UK), according 
to manufacturer’s directions.  Luciferase activity was 
measured as previously described [24].
Chromatin immunoprecipitation assay
Chromatin Immunoprecipitation (ChIP) assays 
were carried out as previously described [53].  Antibodies 
used for ChIP were BRCA1 (Ab4) from Calbiochem 
(Darmstadt, Germany) and c-Myc (N-262) from Santa 
Cruz Technology (CA, USA).  ChIP primer sequences are 
listed in Supplementary Table S3.
Immunofluorescence
Transfected cells were seeded onto coverslips 
and at 72 hr post-transfection were fixed with 4% PFA. 
Following permeabilisation using 0.4% Triton X-100 
(Sigma) in PBS, cells were blocked in 3% BSA/PBS and 
then stained with γ-H2AX and 53BP1 (both Millipore) 
primary antibodies, followed by incubation with 
Alexafluor 488-conjugated goat anti-rabbit and Alexafluor 
568-conjugated goat anti-mouse secondary antibodies 
(Invitrogen).  Coverslips were then mounted onto glass 
slides using ProLong® Gold antifade mountant with DAPI 
(Thermo-Scientific) and imaged on a Nikon Eclipse Ti 
microscope, under a 60× objective.
Reactive oxygen species assays
Cells were plated at 3 × 105 cells per 35 mm dish. 
The next day the media was removed and cells were 
harvested in 1 ml cell dissociation buffer (Gibco, Paisley, 
UK), then pelleted and washed with PBS.  H
2
DCFDA 
(Invitrogen) was added to samples at a concentration 
of 10 μM and assay was carried out according to 
manufacturer’s protocol. Fluorescence of cell suspensions 
was analysed in the BD FACS Calibur flow cytometer. 
Western blot analysis
Immunoblotting was carried out as previously 
described [24].  For detection of phosphorylated proteins, 
cell lysates were collected in RIPA buffer (50 mM 
Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS) supplemented with phosphatase 
inhibitors: 1 mM sodium orthovanadate and 1 mM 
phenylmethanesulfonyl fluoride (PMSF; Sigma-Aldrich), 
as previously described [54].  Antibodies used include 
ERK, AKT, MLC2, pERK1/2, pAKT (Ser473), pMLC2 
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(Ser19) and RhoC (all Cell Signaling, MA, USA), γH2AX 
(Ser139) from Millipore and RhoA (26C4) from Santa 
Cruz.
GST pull-down assay (Rho Activation)
The GST-Rhotekin Rho-binding domain (RBD) 
fusion protein (obtained from Prof. Chris Marshall, 
Cambridge University) was bound to prewashed 
Glutathione-coated Sepharose beads (GE Healthcare, 
Buckinghamshire, UK).  A negative control was also set-
up using GST-only ‘bait’ protein.  Meanwhile, serum-
starved cells were treated with TBXA2R agonist U46619 
(Tocris, Abingdon, UK) at a concentration of 10 nm for 
10 min and then lysed.  The pre-washed GST-bound beads 
were then resuspended in 100 μl PBS to which 500 μg 
of cell lysate was added.  This was rotated at 4°C for 
30 min to allow binding of GST-Rhotekin RBD to GTP-
Rho.  The beads were pelleted and resuspended in protein 
sample buffer and levels of total Rho in whole cell lysate 
and active Rho in GST-Rhotekin RBD and GST-only pull-
down samples were measured by Western blot analysis. 
Wound-scratch assay
Cells were seeded in 24-well plates at a density of 
2 × 105 per well.  When confluent, a sterile yellow tip was 
used to make a vertical ‘wound’ in the centre of the well. 
The wounds were photographed at 10× magnification 
using the Olympus CKX41 microscope at 0 hr and at a 
suitable end time-point and the area of the wounds was 
measured using Cell^B software.  The percentage wound 
closure was calculated by ((Area at 0 hr – area at end 
timepoint)/Area at 0 h)) × 100.
Matrigel-coated boyden chamber assay
Millicell 12 μm cell culture inserts (Millipore) were 
coated with 60 μg BD Matrigel™ matrix (BD Biosciences, 
Oxford, UK) in serum-free media.   The next day, cells 
were washed with serum-free media and 2.5 × 105 cells 
per insert were seeded in serum-free media. To the well 
beneath the insert, 500 μl standard media containing 
10% FCS was added.  The cells were incubated at 37°C 
under 5% CO
2
 for approximately 22 hr.  After this time, 
the membrane inside the inserts for analysing the invaded 
cells, but not for the ‘total cells’ control, were wiped 
with cotton wool.  All inserts were fixed in methanol for 
10 min and then stained with crystal violet for 30 min. 
After removing the crystal violet the inserts were left 
to dry and were then destained in 0.1 M sodium citrate 
and the absorbance was read at 570 nm using Biotrak 
II Visible plate reader.  The percentage of invasive cells 
was calculated as follows: (absorbance of invaded cells/
absorbance of ‘total cells’) × 100.
Tissue microarrays (TMAs)
The breast cancer TMAs used in this study were 
constructed from formalin-fixed paraffin-embedded 
primary tumour blocks by the Northern Ireland Biobank 
(NIB ref: 12-0043) with each tumour sample represented 
by three independent 1 mm diameter cores. Repeat IHC 
for ER, PR and HER2 on the TMA sections confirmed 
the TNBC status of this case cohort. Anti-TBXA2R 
antibody was a kind gift from Therese Kinsella (UCD, 
Ireland).  All antibodies were scored independently by two 
histopathologists blinded to patient clinicopathological 
and outcome data.  TBXA2R was assessed and scored on 
the basis of presence or absence in tumour epithelium. 
Survival analyses
All Kaplan Meier Curves and Hazard Ratio 
Calculations were carried out using the R package 
“Survival”.
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